Skip to Main Content
Contribute Try STAT+ Today

After being forced to reassess its original findings, a U.K. antitrust watchdog has issued a provisional ruling that Pfizer (PFE) and a small generic company engaged in price gouging for an epilepsy pill, causing the National Health Service to unnecessarily overpay for a “vital” medicine.

The decision is the latest in an eight-year odyssey in which the Competition and Markets Authority has sought to prove that the companies unfairly dominated the market for the drug. But its effort has been beset by fines, appeals, and court rulings, which required the agency to go back to the proverbial drawing board in one of its highest-profile attempts to police the pharmaceutical industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment